Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Plant Allergenic Extract [EPC]
Chelidonium Majus Root is a non-standardized plant allergenic extract used primarily in the diagnosis and treatment of specific hypersensitivities. It belongs to the class of allergenic extracts used for skin testing and immunotherapy under medical supervision.
Name
Chelidonium Majus Root
Raw Name
CHELIDONIUM MAJUS ROOT
Category
Non-Standardized Plant Allergenic Extract [EPC]
Drug Count
8
Variant Count
8
Last Verified
February 17, 2026
About Chelidonium Majus Root
Chelidonium Majus Root is a non-standardized plant allergenic extract used primarily in the diagnosis and treatment of specific hypersensitivities. It belongs to the class of allergenic extracts used for skin testing and immunotherapy under medical supervision.
Detailed information about Chelidonium Majus Root
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Chelidonium Majus Root.
Chelidonium Majus Root, derived from the perennial herbaceous plant commonly known as Greater Celandine, is classified pharmacologically as a Non-Standardized Plant Allergenic Extract [EPC]. In the context of modern clinical medicine, this substance is utilized primarily as an antigenic agent for the diagnosis and potential immunotherapy of allergic diseases. Chelidonium Majus belongs to the Papaveraceae (poppy) family and has been historically noted for its complex alkaloid profile. However, its primary clinical application in regulated medicine involves its use as an allergenic extract.
As an allergenic extract, Chelidonium Majus Root is part of a therapeutic class designed to identify and mitigate Type I hypersensitivity reactions (immediate-type allergies). These extracts are prepared by extracting the water-soluble proteins, carbohydrates, and glycoproteins from the root of the plant. Unlike 'standardized' extracts, which have a potency measured by specific bioequivalent units, Chelidonium Majus Root is 'non-standardized,' meaning its potency is typically expressed in terms of weight-to-volume (w/v) ratios or Protein Nitrogen Units (PNU). The FDA has overseen the regulation of these extracts through the Center for Biologics Evaluation and Research (CBER), ensuring that while they are non-standardized, they meet rigorous purity and manufacturing standards.
The mechanism of action of Chelidonium Majus Root extract depends on its clinical application: diagnostic testing or therapeutic immunotherapy.
Diagnostic Mechanism: When used for skin prick testing (SPT) or intradermal testing, the extract is introduced into the epidermis or dermis. If a patient is sensitized to the proteins in Chelidonium Majus, specific Immunoglobulin E (IgE) antibodies bound to the surface of mast cells will recognize the allergens. This recognition triggers mast cell degranulation, releasing inflammatory mediators such as histamine, leukotrienes, and prostaglandins. This results in a 'wheal and flare' reaction—a localized area of swelling and redness—which confirms the patient's sensitivity to the plant.
Therapeutic Mechanism (Immunotherapy): In allergen immunotherapy (AIT), the extract is administered in gradually increasing doses. This process aims to induce immunological tolerance. At the molecular level, this involves a shift in the immune response from a Th2-dominated profile (which promotes IgE production) to a Th1-dominated profile. It also induces the production of 'blocking antibodies' (IgG4), which compete with IgE for allergen binding sites. Furthermore, it promotes the activity of regulatory T-cells (Tregs) that secrete IL-10 and TGF-beta, which suppress the allergic inflammatory cascade.
Traditional pharmacokinetic parameters (Absorption, Distribution, Metabolism, and Elimination) are not typically applied to allergenic extracts in the same way they are to systemic small-molecule drugs, as these extracts are biological mixtures acting locally or through complex immunological signaling.
Chelidonium Majus Root extract is indicated for the following clinical purposes:
Chelidonium Majus Root allergenic extract is available in several specialized forms, primarily for use in clinical settings:
> Important: Only your healthcare provider can determine if Chelidonium Majus Root is right for your specific condition. Because of the risk of severe systemic reactions, including anaphylaxis, these extracts must only be administered by clinicians trained in the management of allergic emergencies.
Dosage for Chelidonium Majus Root is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity levels.
Chelidonium Majus Root extracts may be used in children, but extreme caution is required. Dosing follows the same weight-to-volume logic as adult dosing, but the starting concentration may be even more dilute depending on the child's history of asthma or previous systemic reactions. There is no specific age cutoff, but immunotherapy is generally not initiated in children under the age of 5 due to the difficulty of communicating symptoms of an impending systemic reaction.
No specific dosage adjustments are provided for renal impairment, as the systemic load of the extract is negligible. However, patients with severe renal disease may have altered skin reactivity.
No dosage adjustments are required. While ingested Chelidonium majus herb is associated with hepatotoxicity, the allergenic extract used in small quantities for testing or SCIT does not typically pose a risk to liver function.
Elderly patients may have reduced skin reactivity (false negatives). Dosage should be approached conservatively if the patient has underlying cardiovascular disease, as they may be less able to tolerate the effects of epinephrine if it is needed to treat an allergic reaction.
This medication is never self-administered at home. It must be administered in a clinical setting equipped with emergency resuscitation equipment.
In immunotherapy, if a dose is missed, the next dose may need to be reduced depending on how much time has passed.
An overdose of an allergenic extract can lead to a severe systemic reaction or anaphylactic shock.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Always inform your provider of any new medications or changes in your health status before receiving an injection.
Most patients receiving Chelidonium Majus Root extract for testing or therapy will experience localized reactions. These are generally not dangerous but can be uncomfortable.
> Warning: Stop taking Chelidonium Majus Root and call your doctor immediately if you experience any of these symptoms after an injection or test.
When used correctly as an allergenic extract, there are no documented long-term systemic side effects or organ toxicities. The primary 'long-term' effect is the desired modulation of the immune system. However, it is important to distinguish the allergenic extract from the oral consumption of the raw plant. Chronic oral ingestion of Chelidonium majus has been linked to drug-induced liver injury (DILI), including cholestatic hepatitis. This risk is not associated with the tiny amounts used in allergy testing or SCIT, but patients should be aware of the distinction.
While Chelidonium Majus Root itself may not have a specific individual black box warning, the entire class of Allergenic Extracts carries a general warning regarding the risk of severe systemic reactions.
Report any unusual symptoms to your healthcare provider. Even a 'delayed' reaction that occurs several hours after you leave the clinic should be reported before your next scheduled dose.
Chelidonium Majus Root extract is a potent biological substance. Safety is predicated on careful administration and patient monitoring. It is vital that patients disclose their full medical history, especially any history of asthma, heart disease, or previous severe reactions to stings or medications.
No FDA black box warnings specifically for 'Chelidonium Majus Root' exist as a unique entity, but it is covered under the class-wide warning for Allergenic Extracts. This warning emphasizes that these products are intended for use only by physicians experienced in administering allergenic extracts and that they can cause anaphylaxis, which may be fatal if not treated immediately.
Generally, Chelidonium Majus Root does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.
Alcohol should be avoided on the day of an injection. Alcohol causes vasodilation (widening of blood vessels), which can theoretically increase the rate of allergen absorption and potentially worsen the severity of an allergic reaction.
Immunotherapy is typically a 3-to-5-year commitment. Stopping treatment early may result in the return of allergy symptoms. There is no 'withdrawal' syndrome associated with stopping allergenic extracts, but the clinical benefits will gradually diminish over time.
> Important: Discuss all your medical conditions with your healthcare provider before starting Chelidonium Majus Root. Ensure you have an up-to-date 'Allergy Action Plan' and, if prescribed, a functional epinephrine auto-injector.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even over-the-counter cold medicines can contain antihistamines that interfere with your allergy treatment plan.
Patients allergic to Chelidonium Majus Root may show cross-reactivity with other members of the Papaveraceae family, such as poppies (Papaver somniferum) or Bloodroot (Sanguinaria canadensis). If you have had reactions to these plants, inform your allergist before testing.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Chelidonium Majus Root. A thorough risk-benefit analysis is essential for any biological therapy.
Chelidonium Majus Root extract is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary concern is not direct teratogenicity (birth defects) from the extract itself, but the risk of maternal anaphylaxis. Anaphylaxis can cause a sudden drop in maternal blood pressure, leading to placental hypoperfusion and fetal hypoxia (lack of oxygen).
It is not known whether the allergenic components of Chelidonium Majus Root are excreted in human milk. However, because these are proteins that are likely digested in the infant's gut, the risk to a nursing infant is considered very low. The mother should be monitored for systemic reactions, as the stress of a reaction could affect milk let-down.
Allergenic extracts are used in children, but the decision must be made carefully. Children under 5 may have difficulty describing the early symptoms of anaphylaxis (e.g., 'funny taste in the mouth' or 'itchy throat'), which can delay life-saving treatment. Clinical studies have shown that immunotherapy can be effective in pediatric populations for preventing the 'allergic march' (the progression from rhinitis to asthma).
Elderly patients (over 65) require a careful cardiovascular assessment. The risk of using epinephrine in a patient with coronary artery disease must be weighed against the benefits of allergy treatment. Additionally, skin reactivity decreases with age, which may lead to smaller wheal diameters during diagnostic testing.
There is no evidence that renal impairment alters the response to Chelidonium Majus Root extract. However, patients on dialysis may have altered immune function, and their skin may be more sensitive to the glycerin base used in many extracts, leading to 'irritant' rather than 'allergic' reactions.
While the Chelidonium majus plant is known to be hepatotoxic when ingested in large amounts, the parenteral (injected) allergenic extract does not undergo first-pass hepatic metabolism in a way that would suggest risk to the liver. No dose adjustments are required for patients with liver disease.
> Important: Special populations require individualized medical assessment. Always ensure your allergist is aware of your pregnancy status or any underlying chronic conditions.
Chelidonium Majus Root extract acts as an exogenous antigen. In sensitized individuals, the primary molecular targets are IgE antibodies fixed to the high-affinity FcεRI receptors on mast cells and basophils.
| Parameter | Value |
|---|---|
| Bioavailability | Negligible (Local/Subcutaneous) |
| Protein Binding | N/A (Biological Extract) |
| Half-life | Variable (Proteins degraded within hours) |
| Tmax | 15–20 minutes (Skin reaction) |
| Metabolism | Local Proteolysis |
| Excretion | Renal (as amino acids/peptides) |
Chelidonium Majus Root belongs to the Non-Standardized Plant Allergenic Extract [EPC] class. It is grouped with other allergenic extracts like Ragweed, Timothy Grass, and Oak, although each is specific to the patient's sensitivity.
Medications containing this ingredient
Common questions about Chelidonium Majus Root
Chelidonium Majus Root extract is primarily used in clinical allergy medicine for two main purposes: diagnostic skin testing and allergen immunotherapy. During skin testing, it helps doctors identify if a patient has a specific IgE-mediated allergy to the Greater Celandine plant, which can cause respiratory or skin symptoms. In immunotherapy, also known as 'allergy shots,' the extract is administered in gradually increasing amounts to help the patient's immune system build a tolerance to the plant. This treatment is intended for patients who cannot avoid exposure to the plant and whose symptoms are not well-controlled by standard medications. It is a highly specialized biological product that must be used under the supervision of an allergist.
The most common side effects are localized to the site where the extract was applied or injected. During a skin test, most patients will develop a 'wheal and flare' reaction, which is a small, itchy bump surrounded by redness, similar to a mosquito bite. During immunotherapy injections, patients often experience redness, itching, and swelling at the injection site that may last for a few hours. These local reactions are generally mild and are a sign that the immune system is recognizing the allergen. However, if the swelling becomes larger than a few inches, it should be reported to the doctor. Systemic side effects like hives or sneezing are less common but require monitoring.
It is strongly recommended to avoid alcohol on the days you receive a Chelidonium Majus Root injection or undergo skin testing. Alcohol can cause your blood vessels to dilate and increase your heart rate, which might speed up the absorption of the allergen into your bloodstream. This increased absorption rate can raise the risk of a systemic allergic reaction or make a reaction more severe if one occurs. Furthermore, alcohol can mask the early symptoms of an allergic reaction, such as feeling flushed or lightheaded. To ensure maximum safety, wait at least 24 hours after your injection before consuming alcoholic beverages. Always follow the specific lifestyle restrictions provided by your allergy clinic.
The use of Chelidonium Majus Root allergenic extract during pregnancy is approached with significant caution. It is generally not recommended to start a new course of immunotherapy while pregnant because the risk of a severe systemic reaction (anaphylaxis) could harm the fetus by reducing oxygen supply. However, if a woman is already on a stable maintenance dose and is tolerating it well, her allergist may decide to continue the treatment at that same dose. There is no evidence that the extract itself causes birth defects, but the physiological stress of an allergic reaction is the primary concern. Pregnant women should have a detailed discussion with their specialist to weigh the risks of stopping treatment versus the risks of a potential reaction.
The timeframe for Chelidonium Majus Root extract to work depends on whether it is being used for diagnosis or treatment. For diagnostic skin testing, the results are nearly immediate, with the skin reaction appearing within 15 to 20 minutes of application. For immunotherapy (allergy shots), the process is much slower and requires patience. Most patients enter a 'build-up phase' that lasts 3 to 6 months, during which doses are slowly increased. Significant improvement in allergy symptoms typically begins to appear toward the end of this phase or during the early 'maintenance phase.' For long-lasting results that persist even after the shots are stopped, a full course of 3 to 5 years of treatment is usually required.
Yes, you can stop receiving Chelidonium Majus Root injections suddenly without experiencing physical withdrawal symptoms, as it is not an addictive medication. However, stopping immunotherapy prematurely—especially before completing at least three years of treatment—usually means that your allergy symptoms will eventually return. The immune system requires long-term, consistent exposure to the allergen to maintain the 'tolerance' that the shots provide. If you miss too many doses, you cannot simply restart at your previous dose because your sensitivity may have increased, necessitating a 'step-back' in dosage for safety. If you are considering stopping, discuss a plan with your doctor to see if your symptoms are likely to return.
If you miss a scheduled immunotherapy dose of Chelidonium Majus Root, you should contact your allergy clinic as soon as possible to reschedule. Do not attempt to 'double up' on your next dose or self-administer any extract. The safety of immunotherapy depends on the timing of the doses; if too much time passes between injections, your immune system may become more sensitive to the extract again. Depending on how many weeks have passed since your last shot, your doctor may need to repeat your last dose or even reduce the dose significantly to prevent a systemic reaction. Consistency is key to both the safety and the effectiveness of the treatment.
There is no clinical evidence to suggest that Chelidonium Majus Root allergenic extract causes weight gain. Unlike systemic corticosteroids (such as prednisone), which are known to affect metabolism and appetite, allergenic extracts work specifically on the immune system's response to a particular plant protein. The amount of protein and alkaloid in each injection is extremely small and does not have systemic metabolic effects. If you experience weight changes while on immunotherapy, it is likely due to other factors, such as changes in activity levels, diet, or other medications you may be taking for your allergies. Always discuss unexpected weight changes with your primary care provider.
Chelidonium Majus Root can interact with several types of medications, some of which are very serious. The most critical interaction is with beta-blockers (used for heart conditions and migraines), which can make an allergic reaction much more dangerous and difficult to treat. Other medications, like ACE inhibitors and certain antidepressants (MAOIs), may also increase the risk or severity of reactions. On the other hand, common allergy medications like antihistamines can interfere with skin testing by 'hiding' the allergic response, leading to false-negative results. It is vital to provide your allergist with a complete and updated list of all medications, including supplements, to ensure your treatment is safe.
The concept of 'generic' vs. 'brand name' is slightly different for allergenic extracts like Chelidonium Majus Root compared to standard pills. These are biological products, and while several different laboratories may produce a Chelidonium Majus Root extract, they are all considered 'non-standardized' biologicals rather than generics. Because the manufacturing process can vary between companies, extracts from different manufacturers are not considered interchangeable. If your clinic switches suppliers, your doctor will usually restart your dosing at a lower level or perform a new skin test to ensure the new extract is safe for you at that concentration.